Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

201029 citationsReview

Authors

Marianne Abifadel · Université Claude Bernard Lyon 1

Jihane Pakradouni · Saint Joseph University

Matthieu Collin · Inserm Transfert

Marie‐Elisabeth Samson‐Bouma · Hôpital Bichat-Claude-Bernard

Mathilde Varret · Université Claude Bernard Lyon 1

Jean‐Pierre Rabès · Université de Versailles Saint-Quentin-en-Yvelines

Cathérine Boileau

Abstract

Clinical trials have been launched using RNA interference approaches to reduce PCSK9 expression or specific antibodies targeting and inhibiting PCSK9 interaction with the LDL receptor. They constitute very promising approaches to reducing cholesterol levels and coronary heart disease.

Topics & Keywords

Lipoproteins and Cardiovascular Health Computational Drug Discovery Methods Microbial Metabolism and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Expert Opinion on Therapeutic Patents

Volume 20, Issue 11, pp. 1547-1571

DOI: 10.1517/13543776.2010.518615

Field-Weighted Citation Impact: 5.75